Introducing new ophthalmology drugs to enhance competitive position: The company recently reached an agreement with Novartis to obtain China commercial rights of two anti-VEGF drugs -Lucentis (ranibizumab) and Beovu for the treatment 5 November 2025 | 1:12AM HKT Equity Research China Medical System Holdings (0867.HK): APAC Healthcare Corporate Day 2025 — Key Takeaways: 3Q progress on track with guidance Presenters: Susan Liu - Investor Relations Director of CMS; Yuyao Peng - Chief Financial Officer of Derma ...

Key Takeaways OTLK stock dropped 54.1% after the FDA issued a second CRL for ONS-5010 in wet AMD.The CRL cited insufficient efficacy as ONS-5010 missed the NORSE EIGHT non-inferiority endpoint.OTLK will meet with the FDA for clarity regarding requirements.Shares of Outlook Therapeutics (OTLK) tumbled 54.1% after the FDA issued a second complete response letter (CRL) rejecting its biologics license application (BLA) resubmission for ONS-5010 in wet age-related macular degeneration (wet AMD).The CRL cited a s ...